Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer

Core Insights - Anixa Biosciences is presenting its ovarian cancer CAR-T therapy clinical trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer, scheduled for April 10-13, 2026 [1][3] Group 1: Clinical Trial Presentation - Dr. Robert Wenham will present the status of the Phase 1 clinical trial of lira-cel, which is an autologous T cell therapy targeting the follicle-stimulating hormone receptor (FSHR) in recurrent ovarian cancer [2][4] - The presentation will cover the clinical trial design, objectives, and current status of the ongoing trial [2] Group 2: About Lira-cel - Lira-cel specifically targets FSHR, which is expressed on ovarian cells and certain cancer cells, while sparing healthy tissue [4] - The ongoing Phase 1 trial is enrolling adult women with recurrent ovarian cancer who have progressed after at least two prior therapies [4] Group 3: Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes lira-cel developed in collaboration with Moffitt Cancer Center [5] - The company utilizes a novel CAR-T technology known as chimeric endocrine receptor-T cell (CER-T) technology, which differs from traditional cell therapies [5] - Anixa's vaccine portfolio includes collaborations with Cleveland Clinic to develop vaccines for breast and ovarian cancer, as well as other cancers [5]